Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Erasca stock (Erasca)

Buy Erasca stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

About 9 hours ago


+$0.11 (+3.7%)

Erasca is a biotechnology business based in the US. Erasca shares (ERAS) are listed on the NASDAQ and all prices are listed in US Dollars. Erasca employs 126 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Erasca stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Erasca stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ERAS. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Erasca stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Erasca stock price (NASDAQ: ERAS)

Use our graph to track the performance of ERAS stocks over time.

Erasca shares at a glance

Information last updated 2024-07-14.
Latest market close$2.97
52-week range$1.51 - $3.10
50-day moving average $2.28
200-day moving average $2.11
Wall St. target price$4.57
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.84

Is it a good time to buy Erasca stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Erasca price performance over time

Historical closes compared with the close of $2.97 from 2024-07-12

1 week (2024-07-09) 9.59%
1 month (2024-06-14) 36.87%
3 months (2024-04-16) 53.89%
6 months (2024-01-16) 61.41%
1 year (2023-07-14) 12.93%
2 years (2022-07-15) -55.34%
3 years (2021-07-16) 17.43
5 years (2019-07-12) N/A

Erasca financials

Gross profit TTM $0
Return on assets TTM -21.39%
Return on equity TTM -37.6%
Profit margin 0%
Book value $1.91
Market Capitalization $810.3 million

TTM: trailing 12 months

Erasca share dividends

We're not expecting Erasca to pay a dividend over the next 12 months.

Erasca share price volatility

Over the last 12 months, Erasca's shares have ranged in value from as little as $1.51 up to $3.1. A popular way to gauge a stock's volatility is its "beta".

ERAS.US volatility(beta: 1.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Erasca's is 1.162. This would suggest that Erasca's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Erasca's beta into context you can compare it against those of similar companies.

Erasca overview

Erasca, Inc. , a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc.

Frequently asked questions

What percentage of Erasca is owned by insiders or institutions?
Currently 14.716% of Erasca shares are held by insiders and 55.732% by institutions.
How many people work for Erasca?
Latest data suggests 126 work at Erasca.
When does the fiscal year end for Erasca?
Erasca's fiscal year ends in December.
Where is Erasca based?
Erasca's address is: 3115 Merryfield Row, San Diego, CA, United States, 92121
What is Erasca's ISIN number?
Erasca's international securities identification number is: US29479A1088

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site